Stay updated on FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page.

Latest updates to the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page
- Check7 days agoChange DetectedThe page’s revision/build label was incremented from v3.5.2 to v3.5.3, indicating an implementation update without changing the displayed study details.SummaryDifference0.0%

- Check14 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check43 days agoChange DetectedVersion updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check50 days agoChange DetectedRevision updated to v3.4.3. The previous revision v3.4.2 was removed.SummaryDifference0.0%

- Check79 days agoChange DetectedThe page shows Revision: v3.4.2, replacing the previous Revision: v3.4.1. This is a minor metadata update to the page version.SummaryDifference0.0%

- Check86 days agoChange DetectedMinor page update: Revision from v3.4.0 to v3.4.1 with no changes to study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page.